Biogen and Denali Therapeutics have discontinued development of BIIB122 for early-stage Parkinson's disease. The decision follows Phase 2b LUMA trial results, where BIIB122 did not meet efficacy ...
UCB and Biogen ( BIIB) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a ...
Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing ...
Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant ...
Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...
Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over ...
Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle ...
The trial included 648 patients aged 30 to 80 years with early-stage Parkinson’s disease. Credit: R Photography Background / ...
MILAN, May 27 (Reuters) - Italy's antitrust authority (AGCM) said on Wednesday it had opened an investigation into Biogen ...
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the ...
Biogen Inc. said it will continue development of its experimental Alzheimer’s drug after getting promising though not definitive signs of benefit in a mid-stage study, offering hope for a new approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results